Showing results (251-260 of 269) with videos related to
Sort By:
Pageof 27
The Biochemical Journal|September 20, 2007
Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinaseJeffrey D Carson, Glenn Van Aller, Ruth Lehr, et al.Pancreas|July 14, 2022
Hospital Trends of Acute Pancreatitis During the Coronavirus Disease 2019 PandemicMitchell L Ramsey, Arsheya Patel, Lindsay A Sobotka, et al.Toxicologic Pathology|April 24, 2009
Spontaneous hibernomas in Sprague-Dawley ratsRichard H Bruner, Meliton N Novilla, Catherine A Picut, et al.Cytokine|July 5, 2002
Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma productionSanjay Kumar, Charles R Hanning, Michael R Brigham-Burke, et al.Frontiers in Microbiology|July 23, 2013
Microbial activity in the marine deep biosphere: progress and prospectsBeth N Orcutt, Douglas E Larowe, Jennifer F Biddle, et al.Proceedings of the National Academy of Sciences of the United States of America|May 11, 2006
A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analoguesLata T Gooljarsingh, Christine Fernandes, Kang Yan, et al.Biochemistry|August 29, 2001
Steady-state kinetic characterization of substrates and metal-ion specificities of the full-length and N-terminally truncated recombinant human methionine aminopeptidases (type 2)G Yang, R B Kirkpatrick, T Ho, et al.Protein Expression and Purification|May 12, 2010
Baculovirus production of fully-active phosphoinositide 3-kinase alpha as a p85alpha-p110alpha fusion for X-ray crystallographic analysis with ATP competitive enzyme inhibitorsRobert H Sinnamon, Patrick McDevitt, Beth L Pietrak, et al.Journal of Medicinal Chemistry|July 20, 2007
Highly potent inhibitors of methionine aminopeptidase-2 based on a 1,2,4-triazole pharmacophoreJoseph P Marino, Paul W Fisher, Glenn A Hofmann, et al.Journal of Medicinal Chemistry|October 10, 2008
Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseasesClark A Sehon, Gren Z Wang, Andrew Q Viet, et al.Pageof 27